Monobody

The tenth fibronectin type III domain (human, PDB: 1TTG​)
Variable domain of an antibody's lambda light chain (human, PDB: 2RHE​)

Monobodies are synthetic binding proteins that are constructed using a fibronectin type III domain (FN3) as a molecular scaffold. Monobodies are simple and robust alternative to antibodies for creating target-binding proteins. The term "monobody" was coined in 1998 by the Koide group who published the first paper demonstrating the monobody concept using the tenth FN3 domain of human fibronectin.[1]

Monobodies are generated from combinatorial libraries in which portions of the FN3 scaffold are diversified using molecular display and directed evolution technologies such as phage display, mRNA display and yeast surface display.[2][3] A large number of monobodies that have high affinity and high specificity to their respective targets have been reported.[4][5][6][7][8]

Monobodies belong to the class of molecules collectively called antibody mimics (or Antibody mimetics) and alternative scaffolds that aim to overcome shortcomings of natural antibody molecules. A major advantage of monobodies over conventional antibodies is that monobodies can readily be used as genetically encoded intracellular inhibitors, that is you can express a monobody inhibitor in a cell of choice by simply transfecting the cell with a monobody expression vector.[9][10] This is because of unique characteristics of the underlying FN3 scaffold: small (~90 residues), stable, easy to produce, and its lack of disulfide bonds that makes it possible to produce functional monobodies regardless of the redox potential of the cellular environment, including the reducing environment of the cytoplasm and nucleus. In contrast, most antibodies and antibody fragments dependend on disulfide bonds formation and they must be produced under an oxidizing environment.

The monobody technology has been adopted in the biotechnology industry, most notably by Adnexus, a biotechnology company which has been part of Bristol-Myers Squibb since 2007 under the name of Adnectins (originally as Trinectins by its predecesor, Phylos[11]). An example is pegdinetanib (Angiocept), an antagonist of vascular endothelial growth factor receptor 2 (VEGFR-2), which has entered Phase II clinical trials investigating the treatment of glioblastoma in October 2007.[12][13]

Structure

The wild-type FN3 scaffold, consists of 94 amino acids and has a molecular mass of about 10 kDa, fifteen times smaller than an IgG type antibody and comparable the size of a single variable domain of an antibody. They are based on the structure of human fibronectin, more specifically on its tenth extracellular type III domain. This domain has a structure similar to antibody variable domains, with seven beta sheets forming a beta-sandwich and three exposed loops on each side corresponding to the three complementarity determining regions.[14][15] Monobodies lack binding sites for metal ions and the central disulfide bond.

Monobody Library Designs

Monobodies with high affinity and exquisite specificity for different target molecules can be generated from combinatorial libraries in which portions of the FN3 scaffold are diversified. There are two distinct designs of monobody libraries that have been highly successful. The first type modifies some or all of the loops BC (between the second and third beta sheets), DE (between the forth and fifth beta sheets) and FG (between the sixth and seventh sheets).[16][17] This design creates diversified positions on a convex surface that is suitable for targeting concave surfaces such as enzyme active sites. The second type modifies positions in some or all of the C, D, F and G (or the 3rd, 4th, 6th and 7th) strands in addition to the CD and FG loops.[18] This design creates a flatter, slightly concave surface that is suitable for targeting surfaces typically involved in protein-protein interactions.

See also

References

  1. ↑ , Koide A, Bailey CW, Huang X, Koide S (1998). The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol. 284(4):1141-51.
  2. ↑ , Koide S, Koide A, Lipovšek D (2012). Target-binding proteins based on the 10th human fibronectin type III domain (¹⁰Fn3). Methods Enzymol. 503:135-56.
  3. ↑ , Koide A, Wojcik J, Gilbreth RN, Hoey RJ, Koide S (2012). Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. J Mol Biol. 415:393-405.
  4. ↑ , Wojcik J, Hantschel O, Grebien F, Kaupe I, Bennett KL, Barkinge J, Jones RB, Koide A, Superti-Furga G, Koide S (2010). A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol. 17:519-27.
  5. ↑ , Gilbreth RN, Truong K, Madu I, Koide A, Wojcik JB, Li NS, Piccirilli JA, Chen Y, Koide S (2011). Isoform-specific monobody inhibitors of small ubiquitin-related modifiers engineered using structure-guided library design. Proc Natl Acad Sci U S A. 108:7751-6.
  6. ↑ , Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD,Cerny-Reiterer S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G (2011). Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell 147:306-19.
  7. ↑ , Sha F, Gencer EB, Georgeon S, Koide A, Yasui N, Koide S, Hantschel O (2013). Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains. Proc Natl Acad Sci U S A. 110:14924-9.
  8. ↑ , Stockbridge RB, Koide A, Miller C, Koide S (2014). Proof of dual-topology architecture of Fluc F- channels with monobody blockers. Nat Commun 5:5120.
  9. ↑ , Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD,Cerny-Reiterer S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G (2011). Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell 147:306-19.
  10. ↑ , Sha F, Gencer EB, Georgeon S, Koide A, Yasui N, Koide S, Hantschel O (2013). Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains. Proc Natl Acad Sci U S A. 110:14924-9.
  11. ↑ http://www.ncbi.nlm.nih.gov/pubmed/12204693
  12. ↑ Clinical trial number NCT00562419 for "CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan" at ClinicalTrials.gov
  13. ↑ Bloom L, Calabro V (July 2009). "FN3: a new protein scaffold reaches the clinic". Drug Discov. Today 14 (19–20): 949–55. doi:10.1016/j.drudis.2009.06.007. PMID 19576999.
  14. ↑ Koide A, Koide S (2007). "Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain". Methods Mol. Biol. 352: 95–109. doi:10.1385/1-59745-187-8:95. PMID 17041261., Wojcik J, Hantschel O, Grebien F, Kaupe I, Bennett KL, Barkinge J, Jones RB, Koide A, Superti-Furga G, Koide S (2010). A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol. 17:519-27.
  15. ↑
  16. ↑ , Koide A, Bailey CW, Huang X, Koide S (1998). The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol. 284(4):1141-51.
  17. ↑ , Wojcik J, Hantschel O, Grebien F, Kaupe I, Bennett KL, Barkinge J, Jones RB, Koide A, Superti-Furga G, Koide S (2010). A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol. 17:519-27.
  18. ↑ , Koide A, Wojcik J, Gilbreth RN, Hoey RJ, Koide S (2012). Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. J Mol Biol. 415:393-405.
This article is issued from Wikipedia - version of the Thursday, December 31, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.